Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT

December 5, 2016 updated by: Jeong Min Lee, Seoul National University Hospital

Prospective Evaluation of Local Tumor Progression After Radiofrequency Ablation of Hepatocellular Carcinoma: Effectiveness of Immediate Second-Look Evaluation Using Pre-RFA MRI and Post-RFA CT Registration

Magnetic resonance imaging (MRI) has been widely used for small liver lesion detection and characterization. In patients who undergo RFA, MRI is often performed before RFA, whereas immediate technical success is usually assessed by CT. Conventional visual assessment of two modalities may be more challenging than being anticipated, because acquisition position, respiration, and spatial resolution differ between the two. Therefore, the study purpose is to evaluate the results of software-assisted ablative margin assessment using registration of different pre-and post-RFA modalities compared with the conventional method of side-by-side MRI-CT comparison in patients with HCCs.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

77

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with liver tumor and referred to Radiology for RFA.

Description

Inclusion Criteria:

  • patients (≥ 18 years) who were referred to our radiology department for liver tumor RFA
  • patients who had liver MR images of sufficient quality for pre-RFA evaluation within 30 days before RFA
  • patients with 1-3 tumors (<5 cm)

Exclusion Criteria:

  • Child-Pugh class C
  • any uncorrected coagulopathy
  • hypersensitivity to iodine or other reasons that prevented the performance of post-RFA contrast-enhanced CT

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Local tumor progression (LTP)
Time Frame: 60 months
5-year-LTP rate in HCC between sufficient and insufficient ablative margin groups (according to visual assessment and registration software-assisted assessment)
60 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
technique efficacy
Time Frame: 1 month after RFA
Rate of absence of viable tumor on 1-months follow-up CT scan.
1 month after RFA
immediate technical success on visual assessment
Time Frame: 1 day after RFA
technical success of RFA on post-RFA CT using side-by-side comparison of pre-RFA MRI and post-RFA CT
1 day after RFA
immediate technical success on registration-software assessment
Time Frame: 1 day after RFA
technical success of RFA on post-RFA CT using registration-software assessment between pre-RFA MRI and post-RFA CT
1 day after RFA

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Seoul National University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2010

Primary Completion (Actual)

September 1, 2011

Study Completion (Actual)

October 1, 2016

Study Registration Dates

First Submitted

December 5, 2016

First Submitted That Met QC Criteria

December 5, 2016

First Posted (Estimate)

December 7, 2016

Study Record Updates

Last Update Posted (Estimate)

December 7, 2016

Last Update Submitted That Met QC Criteria

December 5, 2016

Last Verified

December 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SNUH-2010-1412

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe